In-vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates

This publication has 15 references indexed in Scilit:

• In vitro efficacy of levonadifloxacin against methicillin-resistant Staphylococcus aureus (MRSA) including hVISA isolates collected across India
  Indian Journal of Medical Microbiology, 2025
• In Vitro Assessment of Antimicrobial Activity of Novel Fluoroquinolone, Levonadifloxacin (WCK 771) Against Multi-Drug-Resistant Clinical Isolates from Cancer Patients in India
  Microbial Drug Resistance, 2024
• India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care
  Indian Journal of Medical Microbiology, 2022
• Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
  The Lancet, 2022
• In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016–18
  Journal of Antimicrobial Chemotherapy, 2019
• In vitro bactericidal activity of levonadifloxacin (WCK 771) against methicillin- and quinolone-resistant Staphylococcus aureus biofilms
  Journal of Medical Microbiology, 2019
• Penetration of Vancomycin into the Cerebrospinal Fluid: A Systematic Review
  Clinical Pharmacokinetics, 2017
• Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
  Clinical Infectious Diseases, 2011
• Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level
  Journal of Infection and Chemotherapy, 2006
• In Vitro Activity of the New Quinolone WCK 771 against Staphylococci
  Antimicrobial Agents and Chemotherapy, 2004